Charming Medical Limited MCTA PHARMA
Company Overview
Charming Medical Limited, through its subsidiaries, provides beauty and wellness services and products in Hong Kong. The company offers beauty, wellness, and postpartum services, including womb-warming therapy, agarwood moxibustion therapy, traditional chinese medicine (TCM) inspired prenatal massage, and indonesian traditional abdominal binding, as well as beauty, tailor-made, slim (BTS) pelvic detox therapy. It also provides TCM-inspired women's wellness services targeting women of different age groups through its wellness centers; non-hormonal induced lactation therapy, national moisturizing facial, saffron hip therapy, and natural reishi mushroom breast care; and japanese-style facial bone adjustment, needle-free thread embedding, and imperial chinese herbal acne detox therapy. In addition, the company offers TCM head/eyed care therapy services comprising ultrasound therapy, forehead cupping therapy, traditional herbal deer antler hair care, deep cleansing follicle therapy, japanese scalp cleansing, cell activation hair growth therapy, and TCM e-plus eye care therapy; and forehead and temples cupping, hair follicle deep cleaning, TCM deer antler hair care, and hair follicle activation therapies, as well as ultrasonic therapy device. Further, it provides Beauty Lab home herbal uterine care patch; probiotic intimate wash; Yin-nourishing pill; Ginseng soothing anti-allergy moisturizing wash; and southern european olive leaf extract for hair anti-aging and hair loss prevention. Additionally, the company is involved in the provision of consultancy services; and franchise activities. It serves women aged between twenty-five to fifty-five through online and offline channels. The company was founded in 2016 and is headquartered in Causeway Bay, Hong Kong.
Why Investors Should Care
Revenue has grown at a 10.8% CAGR over the past five years.
Carries low leverage with a debt-to-equity ratio of 0.18.
Recent Developments
- Mar 2026 Revenue of $4.81M (-22.7% YoY); net profit $-22.65K.
- Trailing 12 Months Year-on-year growth — revenue -18.9%, earnings -93.8%.
- 5-Year Trend Long-term compounding — revenue CAGR 10.8%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 10.84% |
| 1 Year: | -18.90% |
Compounded Profit Growth
| 5 Years: | - |
| 1 Year: | -93.80% |
Stock Price Performance
| 1 Year: | +319.36% |
| 6 Months: | +0.00% |
| 3 Months: | +0.00% |
| 1 Month: | +0.00% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)68.32 · Neutral
P/E of 419.43 is above the sector median of 24.83 — pricier than peers.
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Compounding revenue at 10.8% over 5 years.
CONS
- Trading at a high P/E of 419.4.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | MCTA Charming Medical Limited PHARMA | 29.36 | 419.43 | $445.63M | 0.00% | 2.33% | -0.87% | 10.84% | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,123.91 | 37.80 | $1.00T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 269.12 | 31.22 | $648.55B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 248.78 | 70.48 | $439.62B | 2.78% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 148.46 | 118.77 | $366.28B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 400.84 | 25.74 | $359.79B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 137.70 | 20.80 | $261.73B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 160.04 | 23.99 | $248.20B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 603.02 | 32.49 | $222.97B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Profit & Loss (Annual)
Figures in USD.
| Metric | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| Revenue | 3.53M | 6.02M | 6.22M | 4.81M |
| Cost of Revenue | 2.04M | 2.10M | 2.04M | 1.80M |
| Gross Profit | 1.49M | 3.91M | 4.18M | 3.01M |
| Operating Expenses | 1.78M | 2.74M | 2.57M | 2.88M |
| Operating Income | -287.50K | 1.17M | 1.62M | 128.87K |
| EBITDA | -189.13K | 1.42M | 1.72M | 365.34K |
| Interest Expense | 20.26K | 26.05K | 20.87K | 15.80K |
| Pretax Income | -420.47K | 1.00M | 1.44M | 133.47K |
| Tax Provision | -84.86K | 181.75K | 236.08K | 156.11K |
| Net Income | -305.12K | 777.81K | 1.20M | -22.65K |
| Diluted EPS | -0.02 | 0.05 | 0.07 | - |
Balance Sheet (Annual)
Figures in USD.
| Metric | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| Total Assets | 6.38M | 4.88M | 5.36M | 9.87M |
| Current Assets | 4.12M | 3.67M | 3.37M | 8.17M |
| Cash & Equivalents | 1.93M | 2.10M | 816.77K | 4.70M |
| Inventory | 66.33K | 28.15K | 26.80K | 25.62K |
| Receivables | 186.64K | 351.61K | 395.90K | 201.48K |
| Total Liabilities | 7.65M | 6.03M | 5.31M | 4.69M |
| Current Liabilities | 7.17M | 5.88M | 4.95M | 4.33M |
| Long Term Debt | - | - | - | - |
| Total Debt | 1.81M | 961.38K | 1.16M | 908.02K |
| Total Equity | -1.16M | -1.08M | 49.24K | 5.18M |
| Shares Outstanding | 16.94M | 16.94M | 16.94M | - |
Cash Flows (Annual)
Figures in USD.
| Metric | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| Operating Cash Flow | 2.43M | 295.43K | 425.89K | -1.22M |
| Investing Cash Flow | -606.19K | -210.60K | -2.23M | -179.01K |
| Financing Cash Flow | -1.43M | 100.14K | 521.30K | 5.29M |
| Capital Expenditure | -606.19K | -210.60K | -287.53K | -339.56K |
| Free Cash Flow | 1.83M | 84.83K | 138.36K | -1.56M |
| Net Change in Cash | 397.33K | 184.98K | -1.28M | 3.90M |
Ratios (Annual)
Figures in %.
| Metric | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| Gross Margin % | 42.3% | 65.1% | 67.2% | 62.6% |
| Operating Margin % | -8.1% | 19.5% | 26.0% | 2.7% |
| Net Margin % | -8.6% | 12.9% | 19.3% | -0.5% |
| ROE % | 26.3% | -72.1% | 2,435.0% | -0.4% |
| ROCE % | 36.6% | -117.7% | 396.6% | 2.3% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | UBS Group AG | 0.16% | 24.25K | $711.83K |
| 2 | Geode Capital Management, LLC | 0.07% | 10.75K | $315.62K |
| 3 | JFS Wealth Advisors, LLC | 0.04% | 5.85K | $171.73K |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for MCTA
NASDAQ TRADE HALT CONTINUES REASON NOT AVAILABLE AT 03:28 AM - Bitget
<a href="https://news.google.com/rss/articles/CBMiY0FVX3lxTE9iWjRYYVQ2S01RYjdCOWhLZFhDaGVveTlmeGFIb2tlVE5TcHNOZ19UWHlsVlBwYk13VVpUOTc3NFczeDZrbU9iZXQtUDQwNG1RLTJESkRYbTdFTEZtYm9OV3Y5WdIBY0FVX3lxTE9iWjRYYVQ2S01RYjdCOWhLZFhDaGVveTlmeGFIb2tlVE…
symbol__ Stock Quote Price and Forecast - CNN
<a href="https://news.google.com/rss/articles/CBMiUEFVX3lxTE1TQzcxMDVmQzVWUWhTbEp0V2pTZk9SSEVvQ3c5VzR0N081Q3VNQjREZXFIZEFxMkoxdm9aZ0ZPbHdLS2pIa002aVlQUEZRbE9a?oc=5" target="_blank">symbol__ Stock Quote Price and Forecast</a> <fon…
MCTA: Charming Medical Limited - Detailed Earnings Estimates - Zacks Investment Research
<a href="https://news.google.com/rss/articles/CBMic0FVX3lxTE1YWW40cEhJYUVBcms0YVpaRlBkWjdWT0xDbktyVTA4LWpRc2lqQnM0V3dDMExYdHJaRTNmejVRSzNpeWljLUJpOWFOblpmU0ZmS0tDMEZFd0k4eTgzTWFvb3l6NGdlWDFQaTBlODByMUpMcFk?oc=5" target="_blank">MCTA: Charmi…
Nasdaq Halts Charming Medical Limited - finance.yahoo.com
<a href="https://news.google.com/rss/articles/CBMiiwFBVV95cUxPTDZ0SU45Y1c5NGIxTVRXOE40bzctZW5aZ0NJbVozbktmUkZUbWRIbTFJUG55T1VMNVpEbjBFVTJfSUNZdWxlQ3RkWFpGN0NJdEk2MUNxZml1U3dOWUFseGRIdlJzZVh5Q2NsM0JFbXBHOTBETEV4NU9BRlFXbllzRUUyLUx1SXlva0dJ?o…
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Charming Medical Ltd. of Class Action Lawsuit and Upcoming Deadlines - MCTA - PR Newswire
<a href="https://news.google.com/rss/articles/CBMivgJBVV95cUxNbWlsakxQaVB0akpKTDNfbmtoTkcxbGRpNWg1RW5kd0NCZWN0NmNrV3pBUVVKSVJpLUgxZ3Zpdmo4UXpyVlBqX0lianZWbkp4N3FQNzE2Y1gtUFcwd0oyUDNYbllVN256Zk1DcXoyYU9OS1VmTzNGT2FlbGd6akMyUDdETEtxZUFhQWhmZF…
Shareholders who lost money in shares Charming Medical Ltd. - GlobeNewswire
<a href="https://news.google.com/rss/articles/CBMimAJBVV95cUxQdUhCLUJuSTFycmRBLWdUUl9nWklEQlhnOFRwa3l5OUFBQnZIa1dYWDZwMElwWWVRSmdjc2lrSFVkRmtHeTRza0lXQVBDd1R4V2FNZ0EwRmpIX0lycVFueDk1RUU4YW1lQkJiTldVZ19od3haSXFmOFIzUy00QTAwWjlwSm1uRTdRczF6N0…
MCTA — Frequently Asked Questions
What is the current share price of Charming Medical Limited (MCTA)?
As of 2026-09-19 21:16 PDT, Charming Medical Limited (MCTA) trades at $29.36 on NasdaqCM. Its 52-week range is $6.20 to $29.36.
What is the market capitalisation of MCTA?
Charming Medical Limited (MCTA) has a market capitalisation of $445.63M on NasdaqCM.
What is the P/E ratio of MCTA?
MCTA trades at a trailing price-to-earnings (P/E) ratio of 419.43. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is 97.20.
What is the return on equity (ROE) of MCTA?
MCTA has a return on equity (ROE) of -0.87%. Its return on capital employed (ROCE) is 2.33%.
Is MCTA a good stock to buy?
This page provides a data-driven analysis of Charming Medical Limited (MCTA), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.